Greenwich LifeSciences (GLSI) Projected to Post Earnings on Thursday

Greenwich LifeSciences (NASDAQ:GLSI) will likely be releasing its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect the company to post earnings of ($0.33) per share for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 20, 2026 at 8:00 AM ET.

Greenwich LifeSciences Price Performance

GLSI stock opened at $15.50 on Tuesday. The company has a 50 day moving average price of $19.16 and a 200 day moving average price of $23.53. Greenwich LifeSciences has a fifty-two week low of $7.78 and a fifty-two week high of $34.10. The stock has a market capitalization of $227.54 million, a PE ratio of -9.87 and a beta of 1.46.

Insider Buying and Selling

In other news, CEO Snehal Patel bought 2,500 shares of the business’s stock in a transaction on Thursday, July 23rd. The shares were purchased at an average price of $13.14 per share, for a total transaction of $32,850.00. Following the purchase, the chief executive officer owned 5,606,602 shares of the company’s stock, valued at approximately $73,670,750.28. The trade was a 0.04% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last quarter, insiders purchased 5,800 shares of company stock valued at $76,618. Insiders own 51.47% of the company’s stock.

Institutional Trading of Greenwich LifeSciences

A number of hedge funds and other institutional investors have recently made changes to their positions in GLSI. XTX Topco Ltd bought a new stake in shares of Greenwich LifeSciences in the fourth quarter worth $217,000. Man Group plc acquired a new position in Greenwich LifeSciences during the fourth quarter worth $590,000. Barclays PLC grew its position in Greenwich LifeSciences by 11.8% in the fourth quarter. Barclays PLC now owns 9,744 shares of the company’s stock valued at $205,000 after purchasing an additional 1,030 shares in the last quarter. State Street Corp grew its position in Greenwich LifeSciences by 19.3% in the fourth quarter. State Street Corp now owns 97,777 shares of the company’s stock valued at $2,054,000 after purchasing an additional 15,831 shares in the last quarter. Finally, Wells Fargo & Company MN increased its stake in Greenwich LifeSciences by 109.6% in the 4th quarter. Wells Fargo & Company MN now owns 7,845 shares of the company’s stock valued at $165,000 after buying an additional 4,102 shares during the last quarter. 4.16% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have recently commented on GLSI. Wall Street Zen cut Greenwich LifeSciences from a “hold” rating to a “sell” rating in a research note on Saturday, June 6th. HC Wainwright increased their target price on Greenwich LifeSciences from $50.00 to $69.00 and gave the stock a “buy” rating in a research note on Tuesday, July 21st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Greenwich LifeSciences in a research note on Friday, May 15th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Greenwich LifeSciences has a consensus rating of “Hold” and a consensus price target of $57.00.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.